飛鹿股份(300665.SZ):終止向特定對象發行股票並簽署相關終止協議
格隆匯11月21日丨飛鹿股份(300665.SZ)公佈,公司於2024年11月21日召開了第四屆董事會第五十次會議和第四屆監事會第三十七次會議,審議通過了《關於終止向特定對象發行股票並簽署相關終止協議的議案》,同意公司終止向特定對象發行股票事項並簽署相關終止協議。
自公司向特定對象發行股票方案披露後,公司董事會、管理層與中介機構等積極推進發行的各項工作。綜合考慮資本市場環境變化、市場融資環境以及公司未來發展規劃等因素,經與相關方充分溝通及審慎分析後,公司決定終止向特定對象發行股票事項並簽署相關終止協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.